June 1, 2023 Xintela’s clinical study with XSTEM for knee osteoarthritis makes good progress Read more
June 1, 2023 Nanologica Delivers Silica to Latin-American Customer for Production of Insulin Read more
May 31, 2023 KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors Read more
May 16, 2023 Strike Pharma and FyoniBio conclude successful cell line development of Strike’s bi-specific antibody and clinical lead candidate Read more
May 4, 2023 Stockholm3 included in American guidelines as a primary test for early detection of prostate cancer Read more
May 3, 2023 Empros Secures 80 MSEK Funding To Support Development Of Obesity Treatment Candidate – EMP16 Read more
May 2, 2023 Xspray announces a rights issue of units of approximately SEK 300 million ahead of Dasynoc product launch Read more
April 13, 2023 AnaCardio reports first patient dosed in the GOAL-HF1 study, a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK Read more
April 12, 2023 Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma Read more
March 23, 2023 Duke-NUS partners Alder Therapeutics to unleash the potential of cell-based regenerative therapy Read more
March 20, 2023 XNK receives certificate of GMP compliance of a manufacturer from the Medical Products Agency Read more
March 14, 2023 Ghrelin treatment in heart failure patients showed increased contractility of the heart Read more
February 23, 2023 Xspray Pharma Partners with EVERSANA for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL) Read more
February 9, 2023 Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform Read more
January 25, 2023 Atrogi announces first patient treated with its ATR-258 ß2 adrenoceptor agonist in a phase I clinical study for the treatment of type 2 diabetes Read more
January 17, 2023 Alder Therapeutics Licenses Two Cell Therapy Programs From DUKE-NUS and Biolamina Read more
November 15, 2022 Flerie Invest AB offentliggör erbjudandehandling avseende uppköpserbjudande till aktieägarna i Toleranzia AB Read more
November 14, 2022 Flerie Invest AB lämnar ett kontant budpliktsbud till aktieägarna i Toleranzia AB Read more
November 2, 2022 Flerie Invest AB har ökat sitt innehav i Toleranzia AB varigenom gränsen för budplikt passerats Read more
September 2, 2022 Flerie Invest AB offentliggör erbjudandehandling avseende uppköpserbjudande till aktieägarna i Xintela AB Read more
August 31, 2022 Flerie Invest AB lämnar ett kontant budpliktsbud till aktieägarna i Xintela AB Read more
August 4, 2022 Flerie Invest AB har ökat sitt innehav i Xintela AB varigenom gränsen för budplikt passerats Read more
October 15, 2021 Flerie Invest leder förvärv av norrländsk läkemedelsfabrik för 455 miljoner kronor Read more
October 15, 2021 Flerie Invest AB leads $52m acquisition of Swedish Biopharma Facility from Charles River Read more
